Hospital Pharmacy最新文献

{"title":"Vancomycin-Induced DRESS Syndrome: A Systematic Review of Case Reports.","authors":"Siva Krishna Adithya Bhumireddy, Sai Shashank Gudla, Anil Kumar Vadaga, Meher Satyavani Nandula","doi":"10.1177/00185787251341739","DOIUrl":"10.1177/00185787251341739","url":null,"abstract":"<p><p><b>Background:</b> Vancomycin-induced Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome is a severe hypersensitivity reaction. It presents with rash, eosinophilia, fever, lymphadenopathy, and multi-organ involvement, most often leading to misdiagnosis and delayed treatment. This systematic review aims to identify risk factors, clinical presentations, and optimal management strategies for vancomycin-induced DRESS. <b>Methods:</b> Systematic search with PRISMA 2020 was conducted in PubMed, Scopus, Web of Science, and Google Scholar. Case reports from 2015 to 2025 were screened and demographic information, clinical presentation, risk factors, diagnostic assessment, and outcomes were extracted. Quality of included reports was evaluated with Joanna Briggs Institute (JBI) Critical Appraisal Checklist. <b>Report:</b> The most common symptoms were rash, fever, eosinophilia, and hepatic/renal dysfunction, which typically appeared 2 to 9 weeks following exposure. Genetic predisposition (HLA associations), renal dysfunction, concomitant medications, and viral reactivation were significant risk factors. Rise of AST was shown after a time, and so diagnosis was difficult. Discontinuing vancomycin, administering corticosteroids, and supportive care were the most preferable interventions, with severe conditions requiring IVIG, plasmapheresis and immunosuppressants. Despite interventions, mortality remains high in elderly and immunocompromised patients. <b>Conclusion:</b> Vancomycin is one of the most frequent causes of antibiotic-induced DRESS syndrome, rarely accompanied by severe organ failure and mortality. Early detection, following consistent diagnosing criteria, and tailored treatment regimens are needed to improve patient outcomes and reduce the risk of mortality and improve wellbeing. More research is needed to explore genetic patterns and develop optimal treatment regimens.</p>","PeriodicalId":13002,"journal":{"name":"Hospital Pharmacy","volume":" ","pages":"00185787251341739"},"PeriodicalIF":0.8,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12102078/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144142434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparing the Efficacy of Liraglutide and Semaglutide on Weight Loss: Experience from the Middle East Gulf Region and Literature Review.","authors":"Wasim S El Nekidy, Haneen Hasan, Emna Abidi, Layth Al Sayegh, Ruba Z Dajani, Samer El-Kaissi, Safa B Hegazin, Jihad Mallat","doi":"10.1177/00185787251340645","DOIUrl":"10.1177/00185787251340645","url":null,"abstract":"<p><p><b>Objective:</b> Available data comparing the efficacy of liraglutide and semaglutide in managing weight loss is limited. The objective of this study was to compare efficacy of both drugs on weight loss. <b>Methods:</b> A retrospective observational cohort study conducted at our quaternary care hospital from June 2018 to July 2022. The study included adults who received either liraglutide or semaglutide during the study period. The primary outcome was weight loss, while secondary outcomes included effects on HbA1c levels and lipid profile. <b>Results:</b> A total of 366 patients were analyzed (122 on liraglutide, 244 on semaglutide). The groups were comparable in mean age (51.00 ± 11.55 vs 51.16 ± 12.35 years, <i>P</i> = 0.521) and baseline mean weight (94.7 ± 19.5 vs 94.6 ± 19.9 kg, <i>P</i> = 0.989). After a median follow-up of 10 (6-17) months for the liraglutide group and 7.5 (6-11) months for the semaglutide group (<i>P</i> < 0.001), the resultant weights were 90.8 ± 19.6 kg for the liraglutide group and 91.1 ± 19.8 kg for the semaglutide group (<i>P</i> < 0.001) when comparing each group to its baseline separately. When comparing the weight loss achieved in each group, liraglutide achieved a median weight loss of -4 (-7 to 0) kg versus -3 (-6 to 0) kg for semaglutide (<i>P</i> = 0.867). The reduction in HbA1c levels with liraglutide was significantly less than with semaglutide: -0.2 (-0.5 to 0.3) versus -0.5 (-1.1 to 0.1), respectively, (<i>P</i> = 0.003). Both drugs significantly lowered LDL and triglycerides. Multivariable linear regression analysis confirmed no significant difference between the drugs [<i>B</i> -0.577, 95% CI -1.87 to 0.7; <i>P</i> = 0.38], while baseline weight, diabetes, and SGLT2 inhibitors were significant factors affecting weight. <b>Conclusion:</b> Both liraglutide and semaglutide were effective in reducing weight, with no significant difference between the two drugs. However, semaglutide was more effective in reducing HbA1c levels.</p>","PeriodicalId":13002,"journal":{"name":"Hospital Pharmacy","volume":" ","pages":"00185787251340645"},"PeriodicalIF":0.8,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12095202/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144142425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmacogenetic Evaluation of Hospitalized Patients Requiring Naloxone for Reversal of Acute Opioid Toxicity.","authors":"Justin Grahl, Megan Mills, Amit Singh, Carolyn Oxencis, Alexander Mohr, Taylor Mancuso, Bi Qing Teng, Ruta Bajorunaite, Thomas Carver, William J Peppard","doi":"10.1177/00185787251339360","DOIUrl":"10.1177/00185787251339360","url":null,"abstract":"<p><p><b>Background:</b> Opioids are utilized for acute pain in hospitalized patients and carry the risk of unintentional toxicity. The relationship between unintentional toxicity within a hospital setting and genetic polymorphisms has not been fully evaluated within the literature to date. Assessment and utilization of pharmacogenetic data may be a way to prevent unintentional toxicity in hospitalized patients and reduce the need for naloxone administration. <b>Objective:</b> This study aimed to provide proof of concept for the comparison of allele frequencies of hospitalized patients who received naloxone for opioid reversal with lab control data allele frequencies to identify variations between groups. <b>Methods:</b> This single-center, exploratory, pilot study enrolled 15 patients. Genotype samples were collected via buccal swab and analyzed using a custom 13 gene panel of genes which impact opioid metabolism. Genes assessed include <i>CYP1A2, CYP3A4/A5, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, UGT2B7, UGT1A3, ABCB1, COMT, OPRM1</i>. The 15 patients were compared to an internal lab control group of 100 patients and separated into preventable and not preventable events for further analysis. <b>Results:</b> <i>CYP3A5</i> genotype was found to be statistically significantly different between the experimental and control groups (<i>P</i> = .004). This statistically significant difference was also seen in <i>CYP3A5</i> phenotypes (<i>P</i> = .038). When comparing preventable and not preventable events, a statistically significant difference was found in both the genotype (<i>P</i> = .030) and phenotype (<i>P</i> = .029) of <i>CYP2C19</i>. Other assessed risk factors included mean MME in the 24 hours preceding naloxone being higher among preventable events and hospital or emergency department admission percent risk being higher among not preventable events. <b>Conclusion:</b> Factors other than pharmacogenetics, including opioid route of administration, medication formulation, and overall hospital admission risk, may play an additive role in unintentional toxicity risk. Future research of genotype-guided opioid dosing in pain management services further adds to calculating the risk of unintentional opioid-related adverse effects with standard dosing of this drug class.</p>","PeriodicalId":13002,"journal":{"name":"Hospital Pharmacy","volume":" ","pages":"00185787251339360"},"PeriodicalIF":0.8,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12092407/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144127528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Significant Published Articles in 2024 for Pharmacy Nutrition Support Practice.","authors":"Roland N Dickerson, Titilola M Afolabi, Angela L Bingham, Todd W Canada, Lingtak Neander Chan, Sarah V Cogle, Anne M Tucker, Vanessa J Kumpf","doi":"10.1177/00185787251337596","DOIUrl":"10.1177/00185787251337596","url":null,"abstract":"<p><p><b>Purpose:</b> The purpose of this article is to assist the pharmacist engaged in nutrition support therapy in staying current with pertinent literature. <b>Methods:</b> Several board-certified nutrition support pharmacists aggregated a list of articles relevant to pharmacy nutrition support that was published in 2024. The list was compiled into a spreadsheet whereby the authors were asked to assess whether the article was considered important. A culled list of publications was then identified whereby at least 5 out of the 8 author participants considered the article to be important for pharmacists practicing in nutrition support. Guideline and consensus papers, important to practice but not ranked, were also included. <b>Results:</b> A total of 160 articles were identified; 7 from the primary literature were voted by the group as being of high importance. Twelve guidelines, position, recommendation, or consensus papers were also identified. The top-ranked articles from the primary literature were summarized and a narrative regarding its implications to pharmacy nutrition support practice were provided. <b>Conclusion:</b> We recommend that pharmacists engaged in nutrition support therapy be familiar with these articles as they pertain to their practice.</p>","PeriodicalId":13002,"journal":{"name":"Hospital Pharmacy","volume":" ","pages":"00185787251337596"},"PeriodicalIF":0.8,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12092416/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144127530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mitigating Risks in Hospital Stock Management: A Structured Method for Validating Excel Files.","authors":"Yasmina Gaoual, Zineb Aliat, Ali Cherif Chefchaouni, Adam Mahyaoui, Oussama Merhom, Younes Rahali","doi":"10.1177/00185787251337614","DOIUrl":"10.1177/00185787251337614","url":null,"abstract":"<p><p><b>Introduction:</b> Validation ensures data integrity, accuracy, and usability, addressing risks such as unauthorized modifications, computational errors, and security vulnerabilities. The validation process includes steps like verifying access controls, formulas, conditional formatting, and cell characteristics to align with predefined specifications. <b>Methods:</b> This study, conducted in the Pharmacy of the Hospital of Specialties in Rabat, focused on validating Excel files (Excel 2013) used for data management to ensure compliance with good practices. The methodology involved collaborative development of a validation protocol, including steps like file identification, access level verification, formula testing, and review of hidden elements, cell characteristics, conditional formatting, and headers/footers. This systematic approach ensured data reliability, transparency, and adherence to regulatory standards. <b>Results and discussion:</b> Results demonstrate that the Excel system meets all validation criteria, with secured data protection, accurate calculations, and user-friendly visual cues for identifying critical stock issues. Conditional formatting enhances usability by prioritizing at-risk items, facilitating prompt action. The validated system supports reliable decision-making and operational efficiency, ensuring consistent and transparent medication management. While this approach provides numerous benefits, including enhanced reliability and compliance, challenges such as resource requirements, dependency on user expertise, and frequent updates pose limitations. Nonetheless, integrating validation principles into hospital pharmacy operations offers a pathway to optimizing digital tools for improved healthcare outcomes.</p>","PeriodicalId":13002,"journal":{"name":"Hospital Pharmacy","volume":" ","pages":"00185787251337614"},"PeriodicalIF":0.8,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12089115/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144119423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Drug-Associated Tendinopathies and Ligament Disorders: Results from a Retrospective Pharmacovigilance Study Using Disproportionality Analysis.","authors":"Kannan Sridharan","doi":"10.1177/00185787251337621","DOIUrl":"10.1177/00185787251337621","url":null,"abstract":"<p><p><b>Background:</b> Tendinopathies and ligament disorders are significant musculoskeletal adverse events associated with various drugs, leading to restricted mobility and reduced quality of life. Although certain drug classes such as fluoroquinolones and corticosteroids have established links to these conditions, there is limited research on other potential drug associations. This study aimed to comprehensively evaluate drugs associated with tendinopathies and ligament disorders using data from the USFDA Adverse Event Reporting System (AERS). <b>Methods:</b> A retrospective pharmacovigilance study utilizing spontaneous reports from the USFDA AERS database between March 2004 and June 2024 was conducted. The Standardized Medical Dictionary for Regulatory Activities (MedDRA) query \"Tendinopathies and ligament disorders\" and relevant Preferred Terms were used to identify cases. Disproportionality analysis was performed using both frequentist and Bayesian methods. Subgroup analyses were conducted by age, gender, and clinical outcomes. <b>Results:</b> Out of 29 153 222 reports, 40 485 unique reports were included, with 6641 related to tendon rupture and 2121 to ligament rupture. Fluoroquinolones, corticosteroids, lipid-modifying agents, immunosuppressants, and bisphosphonates were confirmed to have strong associations with tendon and ligament disorders. Emergent signals were identified for anti-inflammatory drugs, and various other drugs, including vaccines. Hospitalization rates were significantly higher in cases of tendon rupture compared to ligament rupture (<i>P</i> < .0001). <b>Conclusion:</b> This study confirms established drug associations and identifies new signals for tendinopathies and ligament disorders. Continued pharmacovigilance is necessary to validate these findings and enhance our understanding of drug-induced musculoskeletal disorders.</p>","PeriodicalId":13002,"journal":{"name":"Hospital Pharmacy","volume":" ","pages":"00185787251337621"},"PeriodicalIF":0.8,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12089119/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144119350","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Drug Utilization and Potentially Inappropriate Prescriptions Assessment Among Discharged Pediatric Patients in a Tertiary Care Hospital.","authors":"Meeradevi Maratha Muthu, Shamala Balan, Sofea Syahira Salim, Ellya Maisarah Mohamad Idris, Anis Suzanna Nor Azmi","doi":"10.1177/00185787251337624","DOIUrl":"10.1177/00185787251337624","url":null,"abstract":"<p><p><b>Background and Aims:</b> Drug utilization and appropriateness assessment among pediatrics is crucial and relies on relevant evidence generation. The study aimed to analyze drug utilization and prevalence of potentially inappropriate prescriptions (PIP) and determine the risk factors for PIP among discharged pediatric patients in a tertiary care hospital. <b>Methods:</b> The cross-sectional study included discharged pediatric (aged < 18 years) prescriptions received between March and May 2023. Drug utilization was assessed using World Health Organization (WHO) Prescribing Indicators. Appropriateness was evaluated using the prescription intervention categories (implicit tool) and 67-item Key Potentially Inappropriate Drugs in Pediatrics List (KIDs List; explicit tool). Categorical and continuous data were analyzed descriptively. Risk factors of PIP were determined by logistic regression analysis. <b>Results:</b> Overall, 1952 prescriptions (mean age 4.61 ± 4.72 years) containing 3304 drugs and 149 drug types were analyzed. The average number of drugs per prescription was 1.69. The use of generic names and drugs from the Malaysian National Essential Medicines List were 2061 (62.38%) and 2985 (90.35%), respectively. The number of antibiotics and injectables per prescription were 1338 (68.55%) and 1(0.05%), respectively. The prevalence of PIP was 8.15% (n = 159). Sixty-one (3.13%) prescriptions were intervened for inappropriate regimen, mainly involving inappropriate dose (n = 47, 2.41%), and inappropriate frequency (n = 15, 0.77%). Ten drugs (14.93%) from KIDs List were prescribed in 80 prescriptions (4.09%), primarily involving tramadol (n = 40, 2.05%). Number of drugs prescribed (adjusted odds ratio (aOR) = 1.63, 95% CI (1.40, 1.89), <i>P</i> < .001), and ages 28 days to 23 months (aOR = 0.15, 95% CI (0.05, 0.49), <i>P</i> = .001), and 2 to 11 years (aOR = 0.22, 95% CI (0.07, 0.71), <i>P</i> = .011) were identified as PIP risk factors. <b>Conclusion:</b> The study found inconsistencies with WHO recommendations for essential drugs, antibiotics, and generic names. Although PIP prevalence was low, the number of drugs prescribed and age categories were key risk factors, emphasizing the need for structured drug reconciliation and a country-specific safe prescribing tool to minimize PIP in pediatric patients.</p>","PeriodicalId":13002,"journal":{"name":"Hospital Pharmacy","volume":" ","pages":"00185787251337624"},"PeriodicalIF":0.8,"publicationDate":"2025-05-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12089120/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144119343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmacist's Educational Intervention on Disease Knowledge, Medication Adherence, and Health-Related Quality of Life Among Rheumatoid Arthritis Patients: A Single Centre, Open-Label, Randomised Controlled Study.","authors":"Sujita Khadka, Sabina Sankhi, Nirmal Raj Marasine","doi":"10.1177/00185787251337594","DOIUrl":"10.1177/00185787251337594","url":null,"abstract":"<p><p><b>Objective:</b> Pharmacists with their unique roles and responsibilities, play a vital role in improving patients knowledge and medication adherence, ultimately contributing to improved health-related quality of life (HRQoL). This study aims to evaluate the impact of pharmacist-led educational intervention on disease knowledge, medication adherence, and HRQoL among patients with rheumatoid arthritis (RA). <b>Methods:</b> A randomized, single-blind, parallel, controlled study was conducted among 118 patients with RA visiting the outpatient department of the National Center for Rheumatic Diseases, Kathmandu, Nepal. Data on disease knowledge, medication adherence, and HRQoL were collected at baseline and follow-up at 12 weeks. Rheumatoid Arthritis Knowledge Assessment Scale (RAKAS), General Medication Adherence Scale (GMAS), and European Quality of Life Scale (EuroQol) 5-Dimension 5-Level (EQ-5D-5L) were used to measure knowledge level, adherence level, and HRQoL, respectively. <b>Results:</b> At follow-up, disease knowledge significantly improved in the intervention group (IG) (excellent knowledge: 42;71.2% vs 9;15.3% at baseline), while the change was minimal in control group (CG) (12;20.3% vs 22.0% at baseline). Similarly, the IG showed a marked increase in medication adherence (high: 57;96.6% vs 20;33.9% at baseline), with only slight improvement in CG (37;62.7% vs 29;49.2% at baseline). The Proportion of patients with the best HRQoL significantly increased in the IG (48;81.4% vs 17;28.8% at baseline), while it remained unchanged in CG. Statistically significant improvements were observed in disease knowledge, medication adherence and HRQoL scores (<i>P</i> < .01) in the IG. <b>Conclusion:</b> The intervention group demonstrated significantly improved disease knowledge, medication adherence, and HRQoL scores, while control group showed minimal changes, highlighting the effectiveness of pharmacist-led educational intervention in disease management.</p>","PeriodicalId":13002,"journal":{"name":"Hospital Pharmacy","volume":" ","pages":"00185787251337594"},"PeriodicalIF":0.8,"publicationDate":"2025-05-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12089118/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144119454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"IVIG Administration: Lessons from Cross-Institutional Protocol Review.","authors":"Michelle L Payne, Keaton S Smetana, Casey C May","doi":"10.1177/00185787251340651","DOIUrl":"10.1177/00185787251340651","url":null,"abstract":"<p><p><b>Background:</b> Intravenous immunoglobulin (IVIG) is used in the acute care, including neurocritical care, setting for a variety of autoimmune and inflammatory conditions. Incidence and severity of infusion-related reactions have been found to be affected by several key factors, including osmolarity, sodium and IgA content, and infusion rate. The purpose of this study was to survey and synthesize IVIG-related practices across various hospitals into a practical guide for clinicians and provide a reference for reviewing or developing IVIG infusion protocols. <b>Methods:</b> Pharmacists from the Neurocritical Care Society Connect online forum were invited to participate in a survey regarding their institutional protocols related to IVIG infusions in the inpatient setting. <b>Results:</b> Data were collected from 12 participating medical centers, all of which have dedicated neurocritical care units. The most common formulation of IVIG used was Privigen^®, followed by Gammagard^®. Gamunex^®-C was only used at two centers. Starting rates for IVIG infusions ranged from 0.3 to 0.6 mL/kg/hr with increases every 15 to 30 minutes. Maximum infusion rates were heterogenous ranging from 2 to 8 mL/kg/hr and often reduced in high-risk populations, such as renal impairment or older age. Significant variation in medication selection and standardization was identified in pre-medication practices and management of adverse reactions. <b>Conclusion:</b> This study highlights the variability in IVIG administration protocols and underscores the need for standardized practices to enhance patient safety and treatment efficacy.</p>","PeriodicalId":13002,"journal":{"name":"Hospital Pharmacy","volume":" ","pages":"00185787251340651"},"PeriodicalIF":0.8,"publicationDate":"2025-05-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12085551/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144101786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Women and Hyponatremia: An Analysis of Sex Differences in Adverse Drug Reactions.","authors":"Eleonora Castellana, Patricia Madalina Budau, Maria Rachele Chiappetta","doi":"10.1177/00185787251337618","DOIUrl":"https://doi.org/10.1177/00185787251337618","url":null,"abstract":"","PeriodicalId":13002,"journal":{"name":"Hospital Pharmacy","volume":" ","pages":"00185787251337618"},"PeriodicalIF":0.8,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12075165/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144077423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}